12.3 Conscious Sedation
Key Takeaways
- Conscious sedation is a technique in which the use of a drug or drugs produces a state of depression of the nervous system enabling treatment to be carried out, but during which verbal contact with the patient is maintained throughout and airway reflexes are preserved
- Nitrous oxide inhalation sedation is titrated from a low starting concentration up to a maximum of 70% N2O with a minimum of 30% oxygen; it is contraindicated in early pregnancy, vitamin B12 deficiency, middle-ear disease, and pneumothorax
- IV midazolam is titrated at 0.07–0.1 mg/kg with onset in 2–3 minutes and duration of 20–30 minutes; flumazenil 200–300 micrograms IV reverses oversedation but is NOT used to meet discharge criteria
- ASA I–II patients are appropriate for sedation in primary care; ASA III requires additional care and often secondary care; absolute contraindications include severe cardiorespiratory disease, airway obstruction, obstructive sleep apnoea, and pregnancy in the first trimester
- Monitoring for IV sedation must include pulse oximetry, blood pressure, and ECG; the IACSD 2020 standards and SDCEP 2017 guidance (reviewed 2022) remain the current professional framework, with SAAD's 2026 integrating guidance adding mandatory AoMRC minimum standards
Definition
Conscious sedation is defined (SDCEP/IACSD) as a technique in which the use of a drug or drugs produces a state of depression of the nervous system enabling treatment to be carried out, but during which:
- Verbal contact with the patient is maintained throughout
- Airway reflexes are preserved
- The patient can respond to commands and maintain their own airway
This distinguishes conscious sedation from general anaesthesia, where consciousness and airway reflexes are lost. The sedationist's aim is anxiolysis and cooperation, not unconsciousness.
Techniques
1. Nitrous Oxide Inhalation Sedation
Nitrous oxide (N2O) is delivered via a dedicated inhalation sedation machine with a fixed ratio of N2O to oxygen.
| Feature | Detail |
|---|---|
| Starting concentration | ~10% N2O, titrated up |
| Maximum N2O | 70% (with minimum 30% oxygen at all times) |
| Common working level | 30–50% N2O |
| Onset | 2–3 minutes; full effect within 5 minutes |
| Recovery | Rapid — O2 only for last 2–5 minutes; patient ambulant within minutes |
| Equipment | Dedicated sedation machine with fail-safe (cut-out if O2 < 30%) and scavenging |
Safety principles:
- Titrate from low concentration — never start at 50%
- Minimum oxygen 30% at all times (machine fail-safe enforces this)
- Active scavenging to minimise environmental pollution and occupational exposure
- Maintain verbal contact throughout — the patient should feel relaxed but conversational
Contraindications to nitrous oxide:
- Early pregnancy (first trimester) — teratogenic concern
- Vitamin B12 deficiency and pernicious anaemia — N2O oxidises B12, inhibiting methionine synthase
- Middle-ear disease — pressure changes can cause barotrauma
- Pneumothorax — N2O diffuses into closed gas spaces and expands them
- Severe respiratory disease (cannot tolerate 30% O2 reduction is rare, but caution in severe COPD)
- Inability to breathe through the nose (e.g. severe nasal obstruction, upper respiratory infection)
Abuse and occupational risk: Chronic recreational abuse of nitrous oxide causes B12 inactivation, megaloblastic anaemia, subacute combined degeneration of the spinal cord, and peripheral neuropathy. Occupational exposure (dental staff) is reduced by effective scavenging.
2. IV Midazolam Sedation
Midazolam is a short-acting benzodiazepine used for IV sedation in dentistry. It produces sedation, anxiolysis, and antegrade amnesia (patients recall little of the procedure).
| Feature | Detail |
|---|---|
| Dose | 0.07–0.1 mg/kg IV, titrated in small increments |
| Onset | 2–3 minutes |
| Duration | 20–30 minutes (clinical effect); longer amnesia |
| Metabolism | Hepatic; half-life 1.5–3 hours |
| Key effect | Sedation + antegrade amnesia |
| Antagonist | Flumazenil 200–300 micrograms IV (titrated in 100 µg increments) |
Flumazenil is used to reverse oversedation or respiratory depression. Critical points:
- Onset 1–2 minutes; duration 30–60 minutes — shorter than midazolam, so patients can re-sedate after reversal; they must remain monitored
- Flumazenil is NOT used to meet discharge criteria — discharge is a clinical decision based on the patient's baseline state, not reversal status
- Can precipitate seizures in benzodiazepine-dependent patients
3. Oral Premedication
Oral midazolam or temazepam is sometimes used for preoperative anxiolysis, especially in children or needle-phobic adults. Dosing is per BNF and must follow sedation monitoring standards once the drug is given.
Patient Selection: ASA Classification
The American Society of Anesthesiologists (ASA) physical status classification guides sedation patient selection:
| ASA Class | Description | Sedation Suitability |
|---|---|---|
| I | Healthy, no systemic disease | Safe for sedation in primary care |
| II | Mild systemic disease, well controlled | Safe for sedation in primary care |
| III | Severe systemic disease, functional limitation | Requires additional care; often secondary care; dedicated sedationist |
| IV | Severe systemic disease, constant threat to life | Not suitable for dental sedation outside hospital |
| V | Moribund | Emergency only |
Absolute Contraindications to Conscious Sedation
- Severe cardiorespiratory disease (unstable angina, severe heart failure, severe COPD)
- Upper airway obstruction or abnormal anatomy
- Obstructive sleep apnoea (unless in specialist care with appropriate monitoring)
- Pregnancy, first trimester (nitrous oxide) — IV sedation also generally avoided
- Inability to cooperate (cognitive impairment, intoxication)
- Allergy to the sedation agent
- Severe renal or hepatic impairment (drug accumulation)
Monitoring Standards
| Route | Minimum Monitoring |
|---|---|
| Inhalation (N2O) | Pulse oximetry; clinical observation; verbal contact |
| IV midazolam | Pulse oximetry, blood pressure, ECG (continuous); clinical observation |
A trained second person (dental nurse with sedation training) must be present throughout. The sedationist must not act as both operator and sedationist for ASA III+ patients.
Consent and Fasting
- Consent: written, informed consent obtained before sedation; the patient must understand the risks, alternatives, and aftercare instructions.
- Fasting for N2O: no standard fasting requirement — light food is acceptable.
- Fasting for IV sedation: typically 2–6 hours for food and 2 hours for clear fluids, per local policy; the SDCEP guidance emphasises a balanced risk approach rather than strict nil-by-mouth for low-risk agents.
Discharge Criteria
Before discharge after sedation the patient must:
- Be awake and responsive, maintaining their own airway
- Have stable vital signs
- Be able to walk with minimal assistance
- Have a responsible escort to take them home and supervise them for the rest of the day
- Be given written and verbal aftercare advice, including no driving, drinking alcohol, operating machinery, or signing legal documents for 24 hours
Regulatory Framework (UK, 2026)
The IACSD (Intercollegiate Advisory Committee for Sedation in Dentistry) 2020 standards and the SDCEP Conscious Sedation in Dentistry guidance (3rd edition, 2017; reviewed 2022) remain the current professional framework. The IACSD committee was disbanded in January 2026, but the 2020 document is not invalidated. A new IACSD committee is being formed to finalise updated 2026 standards.
SAAD (Society for the Advancement of Anaesthesia in Dentistry) published Guidance on Conscious Sedation for Dentistry 2026 integrating:
- GDC and AoMRC minimum standards (mandatory)
- SDCEP and IACSD professional guidance (best-practice framework)
- Minimum 12 hours of age-appropriate sedation-related verifiable CPD per 5-year cycle for the whole sedation team
- Life support training equivalent to Resuscitation Council UK ILS/PILS
- Staffing models based on ASA classification and procedure complexity
STAC (Standards and Training in Advanced Conscious Sedation) accredits courses leading to independent sedation practice; there is a temporary pause on new applications pending updated standards.
Key training principle: only those trained, competent, and (where required) accredited should provide sedation, and the whole team must maintain current life-support and sedation-specific CPD.
A 35-year-old woman (ASA I) presents for restorative treatment under nitrous oxide inhalation sedation. During titration she mentions she might be 8 weeks pregnant. What is the most appropriate action?
A patient received IV midazolam sedation for wisdom tooth surgery. At the end of the procedure the patient is drowsy but rousable. The sedationist administers flumazenil 200 micrograms IV and the patient becomes alert. What is the correct interpretation of this action for discharge purposes?
Which patient is suitable for conscious sedation with IV midazolam in a primary care dental setting according to ASA classification?
Which minimum monitoring is required for IV midazolam sedation in dentistry, according to IACSD/SDCEP standards?